A case of anti-NPX-2 antibody-positive dermatomyositis resulting in massive haemothorax with acquired factor XIII deficiency

Autoimmune diseases, including dermatomyositis, can be complicated by an acquired autoimmune coagulation factor XIII deficiency, which sometimes results in fatal bleeding. Here, we report the case of a young woman with anti-NPX-2 antibody-positive dermatomyositis who developed massive haemothorax wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Modern rheumatology case reports 2023-12, Vol.8 (1), p.91-94
Hauptverfasser: Matsuda, Takuya, Haga, Taiki, Sakaguchi, Takaaki, Kan, Toshiaki, Otsuka, Yasunori
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 94
container_issue 1
container_start_page 91
container_title Modern rheumatology case reports
container_volume 8
creator Matsuda, Takuya
Haga, Taiki
Sakaguchi, Takaaki
Kan, Toshiaki
Otsuka, Yasunori
description Autoimmune diseases, including dermatomyositis, can be complicated by an acquired autoimmune coagulation factor XIII deficiency, which sometimes results in fatal bleeding. Here, we report the case of a young woman with anti-NPX-2 antibody-positive dermatomyositis who developed massive haemothorax with acquired factor XIII deficiency during treatment, including plasma exchange therapy. Emergency transcatheter arterial embolisation was performed and coagulation factor XIII concentrates (Fibrogammin P® 240 U/day for 5 days) were supplemented. Subsequently, the patient was discharged and managed with oral prednisolone and tacrolimus. Coagulation system test results were followed up regularly and remained within normal limits and the patient progressed without recurrence of bleeding symptoms. Coagulation factor XIII deficiency cannot be assessed without measuring coagulation factor XIII activity because common coagulation-fibrinolytic system test results are not abnormal. The measurement of factor XIII activity should be performed when autoimmune diseases are complicated by unexplained bleeding.
doi_str_mv 10.1093/mrcr/rxad049
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2854968427</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2854968427</sourcerecordid><originalsourceid>FETCH-LOGICAL-c221t-d08c95a8b9d078e3f5d5ee42b4c1811a1f940ce8e14521f5895770c42e30c1c23</originalsourceid><addsrcrecordid>eNpNkL1OwzAURi0Eoqh0Y0YeGQi1HTtxxqrip1IFDCB1i1znhho1cWs70Cw8S5-lT0ZLC2K6n66OznAQuqDkhpIs7ldOu75bqYLw7AidMZ6ySCRMHP_bHdTz_p0QQlMZC5Geok6cJiRJGD9DXwOslQdsy81a1cFEj8-TiOHdnNqijRbWm2A-ABfgKhVs1f48PHbgm3kw9Rs29WZdKe931ExBZcPMOrXCnybMsNLLxjgocKl0sA5PRqPR1lUabaDW7Tk6KdXcQ-9wu-j17vZl-BCNn-5Hw8E40ozREBVE6kwoOc0KkkqIS1EIAM6mXFNJqaJlxokGCZQLRkshM5GmRHMGMdFUs7iLrvbehbPLBnzIK-M1zOeqBtv4nEnBs0Rylm7R6z2qnfXeQZkvnKmUa3NK8l30fBc9P0Tf4pcHczOtoPiDfxPH37m9giQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2854968427</pqid></control><display><type>article</type><title>A case of anti-NPX-2 antibody-positive dermatomyositis resulting in massive haemothorax with acquired factor XIII deficiency</title><source>MEDLINE</source><source>Oxford Journals Online</source><creator>Matsuda, Takuya ; Haga, Taiki ; Sakaguchi, Takaaki ; Kan, Toshiaki ; Otsuka, Yasunori</creator><creatorcontrib>Matsuda, Takuya ; Haga, Taiki ; Sakaguchi, Takaaki ; Kan, Toshiaki ; Otsuka, Yasunori</creatorcontrib><description>Autoimmune diseases, including dermatomyositis, can be complicated by an acquired autoimmune coagulation factor XIII deficiency, which sometimes results in fatal bleeding. Here, we report the case of a young woman with anti-NPX-2 antibody-positive dermatomyositis who developed massive haemothorax with acquired factor XIII deficiency during treatment, including plasma exchange therapy. Emergency transcatheter arterial embolisation was performed and coagulation factor XIII concentrates (Fibrogammin P® 240 U/day for 5 days) were supplemented. Subsequently, the patient was discharged and managed with oral prednisolone and tacrolimus. Coagulation system test results were followed up regularly and remained within normal limits and the patient progressed without recurrence of bleeding symptoms. Coagulation factor XIII deficiency cannot be assessed without measuring coagulation factor XIII activity because common coagulation-fibrinolytic system test results are not abnormal. The measurement of factor XIII activity should be performed when autoimmune diseases are complicated by unexplained bleeding.</description><identifier>ISSN: 2472-5625</identifier><identifier>EISSN: 2472-5625</identifier><identifier>DOI: 10.1093/mrcr/rxad049</identifier><identifier>PMID: 37606624</identifier><language>eng</language><publisher>England</publisher><subject>Autoimmune Diseases - complications ; Autoimmune Diseases - diagnosis ; Dermatomyositis - complications ; Dermatomyositis - diagnosis ; Dermatomyositis - therapy ; Factor XIII ; Factor XIII Deficiency - complications ; Factor XIII Deficiency - diagnosis ; Factor XIII Deficiency - therapy ; Female ; Hemothorax - complications ; Humans</subject><ispartof>Modern rheumatology case reports, 2023-12, Vol.8 (1), p.91-94</ispartof><rights>Japan College of Rheumatology 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c221t-d08c95a8b9d078e3f5d5ee42b4c1811a1f940ce8e14521f5895770c42e30c1c23</citedby><cites>FETCH-LOGICAL-c221t-d08c95a8b9d078e3f5d5ee42b4c1811a1f940ce8e14521f5895770c42e30c1c23</cites><orcidid>0009-0003-5764-4595</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37606624$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsuda, Takuya</creatorcontrib><creatorcontrib>Haga, Taiki</creatorcontrib><creatorcontrib>Sakaguchi, Takaaki</creatorcontrib><creatorcontrib>Kan, Toshiaki</creatorcontrib><creatorcontrib>Otsuka, Yasunori</creatorcontrib><title>A case of anti-NPX-2 antibody-positive dermatomyositis resulting in massive haemothorax with acquired factor XIII deficiency</title><title>Modern rheumatology case reports</title><addtitle>Mod Rheumatol Case Rep</addtitle><description>Autoimmune diseases, including dermatomyositis, can be complicated by an acquired autoimmune coagulation factor XIII deficiency, which sometimes results in fatal bleeding. Here, we report the case of a young woman with anti-NPX-2 antibody-positive dermatomyositis who developed massive haemothorax with acquired factor XIII deficiency during treatment, including plasma exchange therapy. Emergency transcatheter arterial embolisation was performed and coagulation factor XIII concentrates (Fibrogammin P® 240 U/day for 5 days) were supplemented. Subsequently, the patient was discharged and managed with oral prednisolone and tacrolimus. Coagulation system test results were followed up regularly and remained within normal limits and the patient progressed without recurrence of bleeding symptoms. Coagulation factor XIII deficiency cannot be assessed without measuring coagulation factor XIII activity because common coagulation-fibrinolytic system test results are not abnormal. The measurement of factor XIII activity should be performed when autoimmune diseases are complicated by unexplained bleeding.</description><subject>Autoimmune Diseases - complications</subject><subject>Autoimmune Diseases - diagnosis</subject><subject>Dermatomyositis - complications</subject><subject>Dermatomyositis - diagnosis</subject><subject>Dermatomyositis - therapy</subject><subject>Factor XIII</subject><subject>Factor XIII Deficiency - complications</subject><subject>Factor XIII Deficiency - diagnosis</subject><subject>Factor XIII Deficiency - therapy</subject><subject>Female</subject><subject>Hemothorax - complications</subject><subject>Humans</subject><issn>2472-5625</issn><issn>2472-5625</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkL1OwzAURi0Eoqh0Y0YeGQi1HTtxxqrip1IFDCB1i1znhho1cWs70Cw8S5-lT0ZLC2K6n66OznAQuqDkhpIs7ldOu75bqYLw7AidMZ6ySCRMHP_bHdTz_p0QQlMZC5Geok6cJiRJGD9DXwOslQdsy81a1cFEj8-TiOHdnNqijRbWm2A-ABfgKhVs1f48PHbgm3kw9Rs29WZdKe931ExBZcPMOrXCnybMsNLLxjgocKl0sA5PRqPR1lUabaDW7Tk6KdXcQ-9wu-j17vZl-BCNn-5Hw8E40ozREBVE6kwoOc0KkkqIS1EIAM6mXFNJqaJlxokGCZQLRkshM5GmRHMGMdFUs7iLrvbehbPLBnzIK-M1zOeqBtv4nEnBs0Rylm7R6z2qnfXeQZkvnKmUa3NK8l30fBc9P0Tf4pcHczOtoPiDfxPH37m9giQ</recordid><startdate>20231229</startdate><enddate>20231229</enddate><creator>Matsuda, Takuya</creator><creator>Haga, Taiki</creator><creator>Sakaguchi, Takaaki</creator><creator>Kan, Toshiaki</creator><creator>Otsuka, Yasunori</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0003-5764-4595</orcidid></search><sort><creationdate>20231229</creationdate><title>A case of anti-NPX-2 antibody-positive dermatomyositis resulting in massive haemothorax with acquired factor XIII deficiency</title><author>Matsuda, Takuya ; Haga, Taiki ; Sakaguchi, Takaaki ; Kan, Toshiaki ; Otsuka, Yasunori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c221t-d08c95a8b9d078e3f5d5ee42b4c1811a1f940ce8e14521f5895770c42e30c1c23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Autoimmune Diseases - complications</topic><topic>Autoimmune Diseases - diagnosis</topic><topic>Dermatomyositis - complications</topic><topic>Dermatomyositis - diagnosis</topic><topic>Dermatomyositis - therapy</topic><topic>Factor XIII</topic><topic>Factor XIII Deficiency - complications</topic><topic>Factor XIII Deficiency - diagnosis</topic><topic>Factor XIII Deficiency - therapy</topic><topic>Female</topic><topic>Hemothorax - complications</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsuda, Takuya</creatorcontrib><creatorcontrib>Haga, Taiki</creatorcontrib><creatorcontrib>Sakaguchi, Takaaki</creatorcontrib><creatorcontrib>Kan, Toshiaki</creatorcontrib><creatorcontrib>Otsuka, Yasunori</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Modern rheumatology case reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsuda, Takuya</au><au>Haga, Taiki</au><au>Sakaguchi, Takaaki</au><au>Kan, Toshiaki</au><au>Otsuka, Yasunori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A case of anti-NPX-2 antibody-positive dermatomyositis resulting in massive haemothorax with acquired factor XIII deficiency</atitle><jtitle>Modern rheumatology case reports</jtitle><addtitle>Mod Rheumatol Case Rep</addtitle><date>2023-12-29</date><risdate>2023</risdate><volume>8</volume><issue>1</issue><spage>91</spage><epage>94</epage><pages>91-94</pages><issn>2472-5625</issn><eissn>2472-5625</eissn><abstract>Autoimmune diseases, including dermatomyositis, can be complicated by an acquired autoimmune coagulation factor XIII deficiency, which sometimes results in fatal bleeding. Here, we report the case of a young woman with anti-NPX-2 antibody-positive dermatomyositis who developed massive haemothorax with acquired factor XIII deficiency during treatment, including plasma exchange therapy. Emergency transcatheter arterial embolisation was performed and coagulation factor XIII concentrates (Fibrogammin P® 240 U/day for 5 days) were supplemented. Subsequently, the patient was discharged and managed with oral prednisolone and tacrolimus. Coagulation system test results were followed up regularly and remained within normal limits and the patient progressed without recurrence of bleeding symptoms. Coagulation factor XIII deficiency cannot be assessed without measuring coagulation factor XIII activity because common coagulation-fibrinolytic system test results are not abnormal. The measurement of factor XIII activity should be performed when autoimmune diseases are complicated by unexplained bleeding.</abstract><cop>England</cop><pmid>37606624</pmid><doi>10.1093/mrcr/rxad049</doi><tpages>4</tpages><orcidid>https://orcid.org/0009-0003-5764-4595</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2472-5625
ispartof Modern rheumatology case reports, 2023-12, Vol.8 (1), p.91-94
issn 2472-5625
2472-5625
language eng
recordid cdi_proquest_miscellaneous_2854968427
source MEDLINE; Oxford Journals Online
subjects Autoimmune Diseases - complications
Autoimmune Diseases - diagnosis
Dermatomyositis - complications
Dermatomyositis - diagnosis
Dermatomyositis - therapy
Factor XIII
Factor XIII Deficiency - complications
Factor XIII Deficiency - diagnosis
Factor XIII Deficiency - therapy
Female
Hemothorax - complications
Humans
title A case of anti-NPX-2 antibody-positive dermatomyositis resulting in massive haemothorax with acquired factor XIII deficiency
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T19%3A55%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20case%20of%C2%A0anti-NPX-2%20antibody-positive%20dermatomyositis%20resulting%20in%C2%A0massive%20haemothorax%20with%20acquired%20factor%20XIII%20deficiency&rft.jtitle=Modern%20rheumatology%20case%20reports&rft.au=Matsuda,%20Takuya&rft.date=2023-12-29&rft.volume=8&rft.issue=1&rft.spage=91&rft.epage=94&rft.pages=91-94&rft.issn=2472-5625&rft.eissn=2472-5625&rft_id=info:doi/10.1093/mrcr/rxad049&rft_dat=%3Cproquest_cross%3E2854968427%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2854968427&rft_id=info:pmid/37606624&rfr_iscdi=true